{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-037524","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.258560+00:00","generated_at":"2026-05-15T08:09:08.196681+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Citius Oncology reports early LYMPHIR launch momentum with 83% of target accounts in formulary review","bullets":["83% of target accounts have added or are actively progressing LYMPHIR through formulary review.","~135 health plans, covering ~80% of covered lives, secured; no reimbursement denials reported.","Repeat orders from early accounts; initial penetration into community infusion centers underway.","Investigator-sponsored studies: positive topline data in DLBCL at ASTCT 2026; Phase I combo with pembrolizumab completed.","International expansion underway via distribution agreements in Europe and Middle East."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-037524","json":"https://secwatch.observer/filing/0001213900-26-037524.json","markdown":"https://secwatch.observer/filing/0001213900-26-037524.md","text":"https://secwatch.observer/filing/0001213900-26-037524.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026037524/0001213900-26-037524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026037524/ea0284323-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:09:08.196681+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}